Bayer Investors Ignore FDA Boost as Monsanto Legal Costs Swallow €5 Billion

Bayer shares fall 9% YTD as €5 billion Monsanto legal tab outweighs three FDA accelerated approvals and strategic acquisition. Pharma gains, but glyphosate cloud persists.

Bayer’s stock closed Wednesday at €34.52, pushing its year-to-date loss past nine percent and deepening a rift between operational progress and market perception. While the company notched three FDA accelerated approvals for pipeline drugs this week, investors can’t look past the €5 billion being funneled into Monsanto-related litigation during 2026. The tension leaves the pharmaceutical and crop science group trading at a sharp discount to its own fundamentals.

The legal tab — roughly €5 billion earmarked for lawyers and settlements this year alone — starves reinvestment into growth. It also forced a dividend cut to the statutory minimum of €0.11 per share for 2025, a move designed to shore up the balance sheet but one that hardly inspires confidence. Janne Werning of Union Investment captured the mood among large institutional holders: “We want to see earnings, not marketing promises.” Many now label 2026 Bayer’s “year of decision” under CEO Bill Anderson.

None of that, however, changes the fact that the pharma division is delivering. The FDA granted accelerated review status to three compounds: the anticoagulant Asundexian, the kidney drug Kerendia, and Sevabertinib for a specific form of lung cancer. Together with growth from Nubeqa and Kerendia, the pharmaceutical segment is gaining momentum. Crop Science is defending its market position as well. Management has confirmed its currency-adjusted full-year outlook, with the agriculture unit powering the start of the year.

The FDA decisions come alongside a strategic bolt-on acquisition of Perfuse Therapeutics to bolster Bayer’s ophthalmology franchise. The deal signals targeted investment in existing core strengths rather than an unfocused expansion. Yet every operational win is met with a valuation penalty because of the glyphosate cloud. The market is effectively pricing in permanent distrust: shares have fallen nearly 31 percent from their 52-week high of €49.93 set in February, and in the past seven days alone they have dropped about nine percent.

A structural debate hangs over the boardroom. Anderson has publicly committed to all three divisions — Pharmaceuticals, Consumer Health, and Crop Science — but stressed that the company remains “fundamentally open to options.” Major shareholders disagree on what that means. Some demand an “open-ended review of the corporate structure,” while others warn against distraction and a “salami-slicing” approach to potential spin-offs. The absence of a clear path forward adds to the uncertainty.

The arrival of Judith Hartmann as CFO on June 1, 2026, introduces a new voice in capital allocation. She cannot erase the legal liabilities, but she can direct funds more efficiently across a business worth roughly €34.5 billion in market capitalization. The management has explicitly ruled out issuing new shares to finance operations, putting the burden squarely on operational cash flow and cost discipline.

Technically, the stock is sitting in oversold territory with a relative strength index of 33. That reading has historically preceded bounces, but with legal overhang still dominating sentiment, it offers no guarantee. The share price has slipped well below the 50-day moving average of €38.50, although on a 12-month basis it remains nearly 37 percent higher — a reminder that Bayer is not a chronic underperformer, but one whose re-rating has stalled.

The current level around €34 is testing support. If it holds, the pipeline progress and the steady pharma business provide fundamental ballast for a potential recovery. But with the Roundup litigation devouring cash and attention, any upward move will depend on concrete legal relief in the months ahead. For now, Bayer’s science is screaming, but the market is listening to the lawyers.